Advertisement
Singapore markets closed
  • Straits Times Index

    3,224.01
    -27.70 (-0.85%)
     
  • S&P 500

    5,251.77
    +3.28 (+0.06%)
     
  • Dow

    39,758.01
    -2.07 (-0.01%)
     
  • Nasdaq

    16,395.43
    -4.09 (-0.02%)
     
  • Bitcoin USD

    71,136.49
    +1,747.03 (+2.52%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,962.56
    +30.58 (+0.39%)
     
  • Gold

    2,228.00
    +15.30 (+0.69%)
     
  • Crude Oil

    82.39
    +1.04 (+1.28%)
     
  • 10-Yr Bond

    4.2040
    +0.0080 (+0.19%)
     
  • Nikkei

    40,168.07
    -594.66 (-1.46%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • FTSE Bursa Malaysia

    1,530.60
    -7.82 (-0.51%)
     
  • Jakarta Composite Index

    7,288.81
    -21.28 (-0.29%)
     
  • PSE Index

    6,903.53
    +5.36 (+0.08%)
     

Recent Developments for Portola Pharmaceuticals

Recent Developments for Portola Pharmaceuticals

In September 2018, the US FDA granted Portola Pharmaceuticals’ cerdulatinib, an investigational Syk/JAK inhibitor, an orphan drug designation for peripheral T-cell lymphoma (or PTCL) therapy. The FDA grants this designation to support the development of therapies for rare diseases. This designation provides benefits such as seven years of market exclusivity after approval, tax credits for certain clinical trials, and exemption of FDA application fees.